<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01349140</url>
  </required_header>
  <id_info>
    <org_study_id>EXPAREL Dose-Response</org_study_id>
    <nct_id>NCT01349140</nct_id>
  </id_info>
  <brief_title>EXPAREL Dose-Response for Single-Injection Femoral Nerve Blocks</brief_title>
  <official_title>EXPAREL Dose-Response for Single-Injection Femoral Nerve Blocks: A Pharmacodynamics Investigation in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pacira Pharmaceuticals, Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      EXPARELâ„¢, an investigational drug product, is a new formulation of a local anesthetic&#xD;
      (numbing medicine) that is designed to be longer acting than the currently-available local&#xD;
      anesthetics. The purpose of this study is to define the dose-response curve of EXPAREL, an&#xD;
      investigational extended-duration formulation of the local anesthetic bupivacaine, on both&#xD;
      motor and sensory block when applied in a fixed volume adjacent to the femoral nerve.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Putting local anesthetic next to a nerve is a common way of decreasing the pain that patients&#xD;
      feel after surgery. For knee surgery, the local anesthetic is placed next to the femoral&#xD;
      nerve in the middle of the crease where the leg meets the body when bending at the hip joint.&#xD;
      However, the local anesthetic takes away not only sensation-and therefore pain-but also motor&#xD;
      control, leaving muscles weaker. It would greatly improve patient safety if the investigators&#xD;
      could administer a very long-acting local anesthetic that decreased postoperative pain, but&#xD;
      affected muscle strength only minimally. The purpose of this study is to define the&#xD;
      dose-response curve of EXPAREL (also termed SKY0402), an investigational extended-duration&#xD;
      formulation of the local anesthetic bupivacaine, on both motor and sensory block when applied&#xD;
      in a fixed volume adjacent to the femoral nerve.&#xD;
&#xD;
      This investigation will be a Phase 1, prospective, double-masked, human-subjects&#xD;
      dose-response clinical trial.&#xD;
&#xD;
      Enrollment. Subjects will be volunteers of both sexes, age 18 and older. If a volunteer meets&#xD;
      inclusion/exclusion criteria and desires study participation, written, informed consent will&#xD;
      be obtained. Selection for inclusion will not be based on race or socioeconomic status. The&#xD;
      study population of interest includes men and women of all races and socioeconomic status.&#xD;
&#xD;
      Subject preparation. Following written, informed consent, subjects will be admitted to the&#xD;
      UCSD CTRI and have demographic/morphometric data recorded (e.g., age, weight, height), a&#xD;
      medical history recorded, and a brief physical examination. Block placement itself may occur&#xD;
      either in the UCSD CTRI or Hillcrest Outpatient Surgical Center Post Anesthesia Care Unit&#xD;
      (PACU: this is where regional anesthetics are administered on a regular basis for surgical&#xD;
      patients). If the blocks are placed in the PACU, subjects will remain there for two hours and&#xD;
      then moved (accompanied by a physician) on their gurney to the UCSD CTRI where they will&#xD;
      spend the remainder of the study period. Women of childbearing potential will have a urine&#xD;
      pregnancy test. Prior to dosing, baseline quadriceps strength and sensory level measurements&#xD;
      will also be obtained. An intravenous line will be placed in an upper extremity, followed by&#xD;
      external monitors (pulse oximeter, blood pressure, and EKG), and oxygen by nasal cannula (1-6&#xD;
      L/min). Sedation will be provided by a combination of one or more of the following, titrated&#xD;
      to effect: oral valium (10 mg), intravenous fentanyl (50 mcg), and/or intravenous midazolam&#xD;
      (1 mg). Following sterile preparation with chlorhexidine gluconate and isopropyl alcohol, and&#xD;
      once the topical antiseptic is dry, subjects will have bilateral, single-injection,&#xD;
      ultrasound-guided femoral nerve blocks placed using standard UC San Diego techniques as&#xD;
      previously published by the current P.I.&#xD;
&#xD;
      Treatment Group Assignment. The dominant side (left or right) will be randomized to one of&#xD;
      two treatment groups: the higher or lower concentration of the local anesthetic SKY0402. The&#xD;
      non-dominant contralateral side will receive the other possible treatment. The volume of each&#xD;
      and every single-injection femoral nerve block will be 30 mL (standard for femoral nerve&#xD;
      blocks is 30-40 mL). Since volume will remain constant, we will vary the dose of SKY0402 by&#xD;
      varying concentration (volume x concentration = dose). Of note, SKY0402 may be mixed with&#xD;
      normal saline to vary the concentration. Randomization will be based on computer-generated&#xD;
      codes. Randomization will be in blocks of two.&#xD;
&#xD;
      Dose Determination. Initial doses of SKY0402 will begin at 0 mg (low: exclusively normal&#xD;
      saline as the treatment) and 2 mg (high) for the first subject; and 1 mg (low) and 3 mg&#xD;
      (high) for the second subject. Since the volume of each of the bilateral blocks will be 30&#xD;
      mL, the first subject's concentrations will be 0 mg / 30 mL (0%) and 2 mg / 30 mL (0.007%);&#xD;
      while the second subject's concentrations will be 1 mg / 30 mL (0.003%) and 3 mg / 30 mL&#xD;
      (0.010%). Unmasking of treatments will occur following data collection for each subject to&#xD;
      allow determination of dosing for subsequent subjects. The subsequent doses will be between&#xD;
      0-160 mg (0.534%) per side, determined prior to randomization of each subsequent subject. The&#xD;
      specific subsequent doses will increase, remain the same, or decrease, determined by the P.I.&#xD;
      in consultation with the manufacturer of SKY0402. Since the dose-response for SKY0402 remains&#xD;
      unknown for single-injection peripheral nerve blocks, a set &quot;tier&quot; or dose-increase plan&#xD;
      prior to experience with each subject is impossible. However, the dose will never be&#xD;
      increased by more than 20 mg for each side. In addition, doses will always remain within the&#xD;
      range of 0-160 mg (0% - 0.534%) per side, and never exceed a total dose of 160 mg for both&#xD;
      sides combined. Dose escalation will be stopped and only lower doses will be administered&#xD;
      subsequently, if either of the following occurs after study drug administration: one subject&#xD;
      experiences clinically significant motor block persisting more than 7 days or four&#xD;
      consecutive subjects experience clinically significant motor block persisting more than 5&#xD;
      days.&#xD;
&#xD;
      For unsuccessful local anesthetic deposition (defined as local anesthetic that could not be&#xD;
      deposited immediately adjacent to the femoral nerve as viewed by real-time ultrasound) or&#xD;
      subject withdrawal from the study, the subjects' data will not be included in the analysis&#xD;
      and the subject dropped from the study (subjects will always receive compensation for at&#xD;
      least one night in the CTRI--$400-even if they are discharged the day of block placement due&#xD;
      to failed deposition). Remaining subjects will remain within the CTRI and within their bed&#xD;
      until discharged home. Discharge will occur when quadriceps strength has returned to at least&#xD;
      80% of its baseline value. We consider a difference of less than 20 percentage points to be&#xD;
      clinically relevant because a 10% side-to-side strength difference is common, yet&#xD;
      functionally unnoticeable in healthy individuals.4,5 Discharge will occur-at the very&#xD;
      earliest-24 hours following initial block placement. Therefore, the amount of time subjects&#xD;
      will spend in the CTRI will depend upon the duration of local anesthetic action, which will&#xD;
      be variable among subjects and is currently unpredictable without a dose-response curve for&#xD;
      peripheral nerve blocks using SKY0402. We anticipate the duration of study participation for&#xD;
      each subject to be approximately 72 hours. Subjects may withdraw from participation at any&#xD;
      time, and will receive compensation for the time they have participated up until withdrawal&#xD;
      (subjects who withdraw the day of block placement will receive $400). However, if the&#xD;
      research coordinator who is responsible for distributing the compensation is not available at&#xD;
      the time of study withdrawal, then the subject will need to return to the CTRI the following&#xD;
      day (or following Monday if withdrawal occurs over the weekend) for compensation.&#xD;
&#xD;
      Outcome Measurements. We have selected measures that have established reliability and&#xD;
      validity. Staff blinded to treatment group assignment will perform all measures and&#xD;
      assessments. For all measurements, the dominant side will always be tested first, followed by&#xD;
      the contralateral side. Measurements will be performed prior to local anesthetic&#xD;
      administration initiation (&quot;baseline&quot;; Hour 0); as well as specific post-block time points:&#xD;
&#xD;
      Hour Prior to Hour 0 0 0:10 0:20 0:30 0:40 0:50&#xD;
&#xD;
      1 1:15 1:30 1:45 2 2:30 3 3:30 4 5 6 7 8 9 10 24 (Day #2) 27-36 48 (Day #3) 51-60 72 (Day #4)&#xD;
      75-84 96 (Day #5) 99-108 120 (Day #6)&#xD;
&#xD;
      Primary Outcome Measurement&#xD;
&#xD;
      Quadriceps femoris muscle strength: Evaluated using a portable isometric force dynamometer to&#xD;
      measure the maximum voluntary isometric contraction (MVIC) in a seated position with the knee&#xD;
      flexed at 90Âº. This variable will be presented and analyzed as post / pre x 100. For all&#xD;
      measurements, subjects will be asked to take 2 sec to come to maximum effort contracting the&#xD;
      target muscle(s), maintain this effort for 5 sec, and then relax.&#xD;
&#xD;
      Secondary Outcome Measurement&#xD;
&#xD;
      Sensory level: Evaluated using transcutaneous electrical stimulation (TES) in the same manner&#xD;
      as described throughout the anesthesia literature (this is a &quot;gold standard&quot; for regional&#xD;
      anesthesia studies). After clipping any hair, EKG pads will be positioned 2 cm medial to the&#xD;
      proximal patella and quadriceps tendon and attached to a nerve stimulator. The current will&#xD;
      be increased from 0 mA until the subject identifies slight discomfort, at which time the&#xD;
      current is recorded as the TES value and the nerve stimulator turned off. The secondary end&#xD;
      point will be the post-administration maximum current (absolute values in mA).&#xD;
&#xD;
      Safety Assessments Safety assessments will include monitoring of AEs, SAEs, and vital signs&#xD;
      (heart rate, respiratory rate, and blood pressure).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Each subject is assigned two possible doses between 0-80 mg by the investigators based on previous participants' responses to various doses; and, the dominant side is then randomized to either the higher or lower dose. The response for each dose is the primary interest, and not a comparison of the left vs. the right or different dose combinations within each subject. In other words, of interest are the different doses effects on muscle strength and skin sensitivity across participants (eg., Dose A vs Dose B vs Dose C, etc).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
    <masking_description>Investigational Drug Service prepared all study medication, with each dose provided to the caregivers in a 30-mL syringe with IV line extension tubing, both wrapped in opaque tape to retain masking since the relative study drug concentration could be inferred by the opacity of the injectate. One syringe was labeled &quot;Dominant&quot; and the other labeled &quot;Other.&quot; In this manner, all investigators, nursing staff, and subjects remained masked to the specific concentration/dose during all outcome measurements.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Quadriceps Femoris Muscle Strength</measure>
    <time_frame>Baseline until 99 hours</time_frame>
    <description>A dynamometer was used to measure the force produced during a maximum voluntary isometric contraction (MVIC) in a seated position with the knees flexed at 90Â°. The dynamometer was placed on the anterior tibia perpendicular to the tibial crest, just proximal to the medial malleolus. Subjects were asked to take 2 seconds to come to maximum effort contracting the ipsilateral quadriceps femoris, maintain this effort for 5 seconds, and then relax. The measurements immediately before study drug administration were designated baseline, and all subsequent are expressed as a percentage of the baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sensory Effect</measure>
    <time_frame>Baseline until 99 hours</time_frame>
    <description>We evaluated tolerance of transcutaneous electrical stimulation with the same quantitative procedure as described previously. Electrocardiogram pads were placed 2 cm medial to the distal quadriceps tendon and attached to a nerve stimulator (EZstimII, Model ES400; Life-Tech, Stafford, TX). The current was increased from 0 mA until subjects described mild discomfort, at which time the current was recorded as the tolerated level and the nerve stimulator turned off. All sensory measurements are expressed as a percentage of each patient's pre-infusion baseline.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Nerve Block</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The dominant side (left or right) will be randomized to one of two treatment groups: the higher or lower concentration of the local anesthetic EXPAREL. The non-dominant contralateral side will receive the other possible treatment. The volume of each and every single-injection femoral nerve block will be 30 mL (standard for femoral nerve blocks is 30-40 mL).3 Since volume will remain constant, we will vary the dose of EXPAREL by varying concentration (volume x concentration = dose). Of note, EXPAREL may be mixed with normal saline to vary the concentration. Randomization will be based on computer-generated codes. Randomization will be in blocks of two, and stratified by sex.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SKY0402</intervention_name>
    <description>Single-injection femoral nerve block. Initial doses of SKY0402 will begin at 0 mg, and 2 mg (high) for the first subject; and 1 mg (low) and 3 mg (high) for the second subject. The next doses will be between 0-80 mg per side, determined prior to randomization of each subsequent subject. The specific subsequent doses will increase, remain the same, or decrease, determined by the P.I. in consultation with the manufacturer of SKY0402. Doses will always remain within the range of 0-80 mg per side, for a total possible dose of 0-160 mg.</description>
    <arm_group_label>Nerve Block</arm_group_label>
    <other_name>EXPAREL</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  greater than or equal to 18 years old&#xD;
&#xD;
          -  able and willing to have bilateral femoral nerve blocks placed and repeated&#xD;
             motor/sensory testing for 24-120 hours (1-5 days), requiring 1-5 overnight stay(s) in&#xD;
             the UCSD CTRI to allow dissipation of local anesthetic infusion effects to&#xD;
             near-baseline values&#xD;
&#xD;
          -  have the ability to adequately communicate with all study personnel&#xD;
&#xD;
          -  willing and capable of providing written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  daily analgesic use for over one week within the past 6 months&#xD;
&#xD;
          -  opioid use within the previous 4 weeks&#xD;
&#xD;
          -  any neuro-muscular deficit of either femoral nerves and/or quadriceps muscles&#xD;
&#xD;
          -  body mass index &gt; 30 kg/m2&#xD;
&#xD;
          -  current pregnancy&#xD;
&#xD;
          -  incarceration&#xD;
&#xD;
          -  any coagulation disorder&#xD;
&#xD;
          -  uncontrolled anxiety, schizophrenia, or other psychiatric disorder that, in the&#xD;
             opinion of the investigators, may interfere with study assessments or adherence&#xD;
&#xD;
          -  any previous allergic reaction to fentanyl, midazolam, or an amide local anesthetic&#xD;
             (bupivacaine is of the amide local anesthetic class)&#xD;
&#xD;
          -  any previous participation in a SKY0402/EXPAREL study&#xD;
&#xD;
          -  nursing mothers&#xD;
&#xD;
          -  suspected or known drug or alcohol abuse within the previous year; and/or&#xD;
&#xD;
          -  planning on becoming pregnant in the one month following study participation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian M Ilfeld, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University California San Diego</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSD Medical Center Hillcrest</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Ilfeld BM, Eisenach JC, Gabriel RA. Clinical Effectiveness of Liposomal Bupivacaine Administered by Infiltration or Peripheral Nerve Block to Treat Postoperative Pain. Anesthesiology. 2021 Feb 1;134(2):283-344. doi: 10.1097/ALN.0000000000003630. Review.</citation>
    <PMID>33372949</PMID>
  </reference>
  <reference>
    <citation>Ilfeld BM, Gabriel RA, Eisenach JC. Liposomal Bupivacaine Infiltration for Knee Arthroplasty: Significant Analgesic Benefits or Just a Bunch of Fat? Anesthesiology. 2018 Oct;129(4):623-626. doi: 10.1097/ALN.0000000000002386.</citation>
    <PMID>30102616</PMID>
  </reference>
  <results_reference>
    <citation>Ilfeld BM, Malhotra N, Furnish TJ, Donohue MC, Madison SJ. Liposomal bupivacaine as a single-injection peripheral nerve block: a dose-response study. Anesth Analg. 2013 Nov;117(5):1248-56. doi: 10.1213/ANE.0b013e31829cc6ae.</citation>
    <PMID>24108252</PMID>
  </results_reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>May 4, 2011</study_first_submitted>
  <study_first_submitted_qc>May 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2011</study_first_posted>
  <results_first_submitted>January 29, 2020</results_first_submitted>
  <results_first_submitted_qc>March 23, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 25, 2021</results_first_posted>
  <last_update_submitted>March 23, 2021</last_update_submitted>
  <last_update_submitted_qc>March 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Brian M. Ilfeld, MD, MS</investigator_full_name>
    <investigator_title>Associate Professor, In Residence</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>We enrolled 14 subjects, and therefore &quot;Protocol Enrollment&quot; is &quot;14&quot;. However, each leg of each subject was treated separately with a different dose of liposomal bupivacaine (Exparel); and, therefore the number of units analyzed is 28.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Nerve Block</title>
          <description>EXPAREL: active liposome bupivacaine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14">We enrolled 14 subjects, and therefore &quot;Protocol Enrollment&quot; is &quot;14&quot;. However, each leg of each subject was treated separately with a different dose of liposomal bupivacaine (Exparel); and, therefore the number of units for each subject was 2 and the total number of units analyzed was 28.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14">We enrolled 14 subjects, and therefore &quot;Protocol Enrollment&quot; is &quot;14&quot;. However, each leg of each subject was treated separately with a different dose of liposomal bupivacaine (Exparel); and, therefore the number of units for each subject was 2 and the total number of units analyzed was 28.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Nerve Block</title>
          <description>Exparel: liposome bupivacaine</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35" lower_limit="20" upper_limit="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Quadriceps Femoris Muscle Strength</title>
        <description>A dynamometer was used to measure the force produced during a maximum voluntary isometric contraction (MVIC) in a seated position with the knees flexed at 90Â°. The dynamometer was placed on the anterior tibia perpendicular to the tibial crest, just proximal to the medial malleolus. Subjects were asked to take 2 seconds to come to maximum effort contracting the ipsilateral quadriceps femoris, maintain this effort for 5 seconds, and then relax. The measurements immediately before study drug administration were designated baseline, and all subsequent are expressed as a percentage of the baseline.</description>
        <time_frame>Baseline until 99 hours</time_frame>
        <population>Each of 14 subjects had a different dose of medication administered to each the left and right sides, and therefore there were 14 subjects, 28 units analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Nerve Block</title>
            <description>Exparel: liposome bupivacaine</description>
          </group>
        </group_list>
        <measure>
          <title>Quadriceps Femoris Muscle Strength</title>
          <description>A dynamometer was used to measure the force produced during a maximum voluntary isometric contraction (MVIC) in a seated position with the knees flexed at 90Â°. The dynamometer was placed on the anterior tibia perpendicular to the tibial crest, just proximal to the medial malleolus. Subjects were asked to take 2 seconds to come to maximum effort contracting the ipsilateral quadriceps femoris, maintain this effort for 5 seconds, and then relax. The measurements immediately before study drug administration were designated baseline, and all subsequent are expressed as a percentage of the baseline.</description>
          <population>Each of 14 subjects had a different dose of medication administered to each the left and right sides, and therefore there were 14 subjects, 28 units analyzed.</population>
          <units>percentage of baseline measurement</units>
          <param>Number</param>
          <units_analyzed>side of the body (left or right)</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>side of the body (left or right)</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Leg #1: Dose 0 mg nondominant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Unavailable due to observation error by research nurse.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leg #2: Dose 0 mg nondominant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Unavailable due to observation error by research nurse.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leg #3: Dose 0 mg nondominant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leg #4: Dose 0 mg dominant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leg #5: Dose 1 mg dominant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leg #6: Dose 2 mg Nondominant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Unavailable due to observation error by research nurse.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leg #7: Dose 3 mg Dominant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leg #8: Dose 4 mg dominant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Unavailable due to observation error by research nurse.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leg #9: Dose 7 mg nondominant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Unavailable due to observation error by research nurse.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leg #10: Dose 10 mg nondominant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Unavailable due to observation error by research nurse.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leg #11: Dose 15 mg dominant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Unavailable due to observation error by research nurse.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leg #12: Dose 20 mg dominant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Unavailable due to observation error by research nurse.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leg #13: Dose 25 mg dominant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leg #14: Dose 30 mg dominant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leg #15: Dose 35 mg nondominant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leg #16: Dose 40 mg nondominant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leg #17: Dose 40 mg nondominant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leg #18: Dose 50 mg nondominant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leg #19: Dose 60 mg dominant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leg #20: Dose 60 mg dominant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leg #21: Dose 60 mg dominant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leg #22: Dose 60 mg nondominant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leg #23: Dose 70 mg dominant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leg #24: Dose 80 mg dominant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leg #25: Dose 80 mg dominant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leg #26: Dose 80 mg nondominant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leg #27: Dose 80 mg nondominant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leg #28: Dose 80 mg nondominant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sensory Effect</title>
        <description>We evaluated tolerance of transcutaneous electrical stimulation with the same quantitative procedure as described previously. Electrocardiogram pads were placed 2 cm medial to the distal quadriceps tendon and attached to a nerve stimulator (EZstimII, Model ES400; Life-Tech, Stafford, TX). The current was increased from 0 mA until subjects described mild discomfort, at which time the current was recorded as the tolerated level and the nerve stimulator turned off. All sensory measurements are expressed as a percentage of each patient's pre-infusion baseline.</description>
        <time_frame>Baseline until 99 hours</time_frame>
        <population>Each of 14 subjects had a different dose of medication administered to each the left and right sides, and therefore there were 14 subjects, 28 units analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Nerve Block</title>
            <description>Exparel: liposome bupivacaine</description>
          </group>
        </group_list>
        <measure>
          <title>Sensory Effect</title>
          <description>We evaluated tolerance of transcutaneous electrical stimulation with the same quantitative procedure as described previously. Electrocardiogram pads were placed 2 cm medial to the distal quadriceps tendon and attached to a nerve stimulator (EZstimII, Model ES400; Life-Tech, Stafford, TX). The current was increased from 0 mA until subjects described mild discomfort, at which time the current was recorded as the tolerated level and the nerve stimulator turned off. All sensory measurements are expressed as a percentage of each patient's pre-infusion baseline.</description>
          <population>Each of 14 subjects had a different dose of medication administered to each the left and right sides, and therefore there were 14 subjects, 28 units analyzed.</population>
          <units>percentage of baseline measurement</units>
          <param>Number</param>
          <units_analyzed>side of the body (left or right)</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>side of the body (left or right)</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Leg #1: Dose 0 mg nondominant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leg #2: Dose 0 mg nondominant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leg #3: Dose 0 mg nondominant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="486"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leg #4: Dose 0 mg dominant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leg #5: Dose 1 mg dominant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leg #6: Dose 2 mg Nondominant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Subject never exhibited a sensory block &gt;100% of baseline</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leg #7: Dose 3 mg Dominant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Subject never exhibited a sensory block &gt;100% of baseline</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leg #8: Dose 4 mg dominant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leg #9: Dose 7 mg nondominant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Subject never exhibited a sensory block &gt;100% of baseline</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leg #10: Dose 10 mg nondominant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leg #11: Dose 15 mg dominant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leg #12: Dose 20 mg dominant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leg #13: Dose 25 mg dominant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leg #14: Dose 30 mg dominant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Subject never exhibited a sensory block &gt;100% of baseline</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leg #15: Dose 35 mg nondominant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leg #16: Dose 40 mg nondominant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Subject never exhibited a sensory block &gt;100% of baseline</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leg #17: Dose 40 mg nondominant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leg #18: Dose 50 mg nondominant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leg #19: Dose 60 mg dominant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leg #20: Dose 60 mg dominant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leg #21: Dose 60 mg dominant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leg #22: Dose 60 mg nondominant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leg #23: Dose 70 mg dominant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="229"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leg #24: Dose 80 mg dominant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="363"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leg #25: Dose 80 mg dominant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="325"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leg #26: Dose 80 mg nondominant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leg #27: Dose 80 mg nondominant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leg #28: Dose 80 mg nondominant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Nerve Block</title>
          <description>Exparel: liposome bupivacaine</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>rash</sub_title>
                <description>rash in participant who received saline</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Brian Ilfeld, MD, MS</name_or_title>
      <organization>University California San Diego</organization>
      <phone>1-858-444-5949</phone>
      <email>bilfeld@ucsd.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

